Bristol-Myers Squibb: Pulmonary Fibrosis trials

The registry lists 11 Pulmonary Fibrosis studies with Bristol-Myers Squibb as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 3Phase 2 4Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Antifibrotic Therapy Decision-Making in Pulmonary FibrosisNot yet recruitingNCT07722507
• Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisNot yet recruitingNCT07441408Phase 3
• A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisCompletedNCT04308681Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisTerminatedNCT03142191Phase 2Results posted
• Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisCompletedNCT01766817Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisActive, not recruitingNCT06025578Phase 3
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisActive, not recruitingNCT06003426Phase 3
• A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327CompletedNCT04069143Phase 1
• A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy ParticipantsCompletedNCT03981094Phase 1
• Safety and PK Study of CC-90001 in Subjects With Pulmonary FibrosisCompletedNCT02510937Phase 1
• A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT01203943Phase 2